A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Novartis
Merck Sharp & Dohme LLC
Novartis
Ipsen
DualityBio Inc.
Constellation Pharmaceuticals
Incyte Corporation
Amgen
Genentech, Inc.
Arno Therapeutics